HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CSC-3436

inhibitor of TWIST-induced epithelial-mesenchymal transition in head and neck cancer cells

Also Known As:

2-(3-hydroxyphenyl)-5-methylnaphthyridin-4-one; CSC3436

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Naphthyridines: 2
      - CSC-3436: 4

Experts

1.	Way, Tzong-Der: 3 articles (12/2021 - 08/2016)
2.	Kuo, Sheng-Chu: 3 articles (01/2019 - 06/2015)
3.	Ho, Chi-Tang: 2 articles (12/2021 - 01/2019)
4.	Cheng, Yi-Ching: 1 article (12/2021)
5.	Chou, Chun-Hung: 1 article (12/2021)
6.	Huang, Chun-Chen: 1 article (12/2021)
7.	Lin, Ying-Chao: 1 article (12/2021)
8.	Wang, Hao-Kuang: 1 article (12/2021)
9.	Chen, Chiung-Tong: 1 article (01/2019)
10.	Hung, Chao-Ming: 1 article (01/2019)

Related Diseases

1.	Triple Negative Breast Neoplasms 12/01/2021 - "In this study, we investigated the effect of 2-(3-hydroxyphenyl)-5-methylnaphthyridin-4-one (CSC-3436), an useful flavonoid, to overcome the TRAIL-resistant triple negative breast cancer (TNBC) cells. " 12/01/2021 - "CSC-3436 sensitizes triple negative breast cancer cells to TRAIL-induced apoptosis through ROS-mediated p38/CHOP/death receptor 5 signaling pathways."
2.	Neoplasms (Cancer) 08/15/2016 - "Moreover, CSC-3436 displayed strong and selective growth inhibition on cancer cells. " 01/01/2019 - "Interestingly, CSC-3436 reduced EMT, cancer stemness, and migration/invasion abilities through the inhibition of the Twist/Bmi1-Akt/β-catenin pathway. " 08/15/2016 - "The combination of tamoxifen and CSC-3436 produced stronger tumor growth inhibition compared with CSC-3436 or tamoxifen alone treatments in vivo. " 06/01/2015 - "Our results reveal the cellular events in which CSC-3436 induces tumor cell death and demonstrate that CSC-3436 is a potential tubulin-disrupting agent for antitumor therapy against NSCLC."
3.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/01/2015 - "To investigate the anticancer therapeutic potential of a new synthetic compound, 2-(3-hydroxyphenyl)-5-methylnaphthyridin-4-one (CSC-3436), on non-small cell lung cancer (NSCLC) cells. " 06/01/2015 - "The newly synthesized 2-arylnaphthyridin-4-one, CSC-3436, induces apoptosis of non-small cell lung cancer cells by inhibiting tubulin dynamics and activating CDK1."
4.	Ataxia Telangiectasia (Louis Bar Syndrome) 06/01/2015 - "DNA damage response kinases, including ataxia telangiectasia mutated (ATM), ATM and Rad3-related, DNA-dependent protein kinase, checkpoint kinase 1, and checkpoint kinase 2, were phosphorylated and activated by CSC-3436. "
5.	Squamous Cell Carcinoma of Head and Neck 01/01/2019 - "Most importantly, our findings provided new evidence that CSC-3436 played a crucial role in therapeutic targeting to Bmi1 and its molecular pathway in HNSCC, and it will be valuable in prognostic prediction and treatment." 01/01/2019 - "CSC-3436 inhibits TWIST-induced epithelial-mesenchymal transition via the suppression of Twist/Bmi1/Akt pathway in head and neck squamous cell carcinoma."

Related Drugs and Biologics

1.	Flavonoids
2.	Checkpoint Kinase 2
3.	TNF-Related Apoptosis-Inducing Ligand Receptors
4.	DNA-Activated Protein Kinase
5.	Catenins
6.	Tubulin
7.	Tamoxifen
8.	Phosphotransferases (Kinase)
9.	Checkpoint Kinase 1

Related Therapies and Procedures

1.	Therapeutics